<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01588626</url>
  </required_header>
  <id_info>
    <org_study_id>D5133C00001</org_study_id>
    <nct_id>NCT01588626</nct_id>
  </id_info>
  <brief_title>Study to Assess the Pharmacokinetics of AZD6140 After Single Dose in Healthy Japanese Male Volunteers</brief_title>
  <official_title>A Phase I, Single Centre, Open Study to Assess the Pharmacokinetics of Oral AZD6140 After Single Dose in Healthy Japanese Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacokinetics of AZD6140 and its active
      metabolite, safety, tolerability of AZD6140 following single administration in healthy male
      Japanese volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Single Centre, Open Study to Assess the Pharmacokinetics of oral AZD6140 after
      Single Dose in Healthy Japanese Male Volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Description of pharmacokinetics for AZD6140 in terms of: Cmax, tmax, t½, AUC(0-t), AUC, CL/F, Vz/F, MRT, and AUC and Cmax ratios of AR-C124910XX to AZD6140, following single administration of 90 mg dose of AZD6140 in healthy Japanese volunteers.</measure>
    <time_frame>From day 1 (pre-dose) till Day 4 (72h)</time_frame>
    <description>Maximum Concentration (Cmax), Time to reach maximum (peak) plasma concentration (tmax), Terminal plasma half-life (t½), Area under the plasma concentration-time curve from time zero to time t (AUC(0-t)),Area under the plasma concentration-time curve (AUC), Apparent total clearance of the drug from plasma after oral administration (CL/F), Apparent volume of distribution during terminal phase after non-intravenous administration (Vz/F), Mean residence time (MRT), and AUC and Cmax ratios of AR-C124910XX to AZD6140,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of pharmacokinetics profile for AR-C124910XX, which is AZD6140 active metabolite, in terms of: Cmax, tmax, t½, AUC(0-t), AUC, CL/F, Vz/F, MRT, and AUC, following single administration of 90 mg dose of AZD6140 in healthy Japanese volunteers.</measure>
    <time_frame>From day 1 (pre-dose) till Day 4 (72h)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AZD6140 Safety and tolerability profile in terms of: adverse events, vital signs (blood pressure and pulse rate), electrocardiograms (ECGs), laboratory variables</measure>
    <time_frame>From Day -1 (pre-dose) up to 7-10 days after dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>AZD6140</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single administration of 90 mg dose of AZD6140</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD6140</intervention_name>
    <description>tablet</description>
    <arm_group_label>AZD6140</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subject aged between 20 to 45 years inclusive

          -  Body mass index (BMI=weight/height2) between 18.0 to 27.0 kg/m2 inclusive

          -  Body weight between 50.0 to 85.0 kg inclusive Provision of written informed consent

        Exclusion Criteria:

          -  Clinically significant abnormalities in clinical chemistry, haematology or urinalysis
             results as judged by the investigator, or positive results on screening tests for
             serum hepatitis B surface antigen and hepatitis C antibody, syphilis and human immu

          -  Supine blood pressure &gt; 150 mmHg systolic or &gt; 95 mmHg diastolic or supine pulse &gt; 90
             beats per minute (after resting for 10 minutes) Personal or family history of bleeding
             disorders, or reasonable suspicion of vascular malformations, including aneurysms

          -  Personal or familial predisposition for thrombotic disorders Clinically significant
             medical history, including psychiatric disorders and severe allergies
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hidenori Komori, MD PHD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D Japan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kyoko Matsuguma</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyushu Clinical Pharmacology Research Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2012</study_first_submitted>
  <study_first_submitted_qc>April 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2012</study_first_posted>
  <last_update_submitted>July 12, 2012</last_update_submitted>
  <last_update_submitted_qc>July 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteer</keyword>
  <keyword>Japanese males</keyword>
  <keyword>PK study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

